Filing Flows › Maravai Lifesciences Holdings (MRVI) › Guidance & outlook
Maravai Lifesciences Holdings (MRVI) guidance and outlook
Maravai Lifesciences Holdings (MRVI) raised its guidance on Nov 4, 2026: Revenue $212M–$216M for FY2026; EBITDA $40.0M–$42.0M for FY2026. Maravai Lifesciences Holdings' 10-Q filed Nov 5, 2026 makes 15 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $212M–$216M | raised |
| EBITDA | FY2026 | $40.0M–$42.0M | raised |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We intend to continue investing in research and development to support our customers’ demand for innovation.
- In particular, we expect to incur meaningful share-based compensation expense in the future.
- We expect cost of revenue to remain below prior-year levels as a percentage of revenue as we continue to realize the benefits of our restructuring actions.
- We expect our selling, general and administrative expenses to remain below prior-year levels as we continue to realize the benefits of our restructuring actions, while remaining relatively stable for the remainder of the fiscal year.
- We expect our research and development expenses to remain below prior-year levels as we continue to realize the benefits of our restructuring actions, while remaining relatively stable for the remainder of the fiscal year.
- We are subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Topco LLC and will be taxed at the prevailing corporate tax rates.
- Our CODM reviews segment performance along with forecasts and other non-financial information in determining how to allocate resources.
- There is no stated term for the TRA, and the TRA will continue until all tax benefits have been utilized or expired unless we exercise our right to terminate the TRA for an agreed-upon amount.
- We plan to utilize our existing cash on hand primarily to fund our commercial and marketing activities associated with our products and services, and continued research and development initiatives.
- We expect to fund any such payments using cash on hand and cash generated from operations.
- There can be no assurance that we will be able to finance our obligations under the TRA.
- Although the actual timing and amount of any payments that may be made under the TRA will vary, the aggregate payments that we will be required to make to MLSH 1 and MLSH 2 may be substantial.
Maravai Lifesciences Holdings' latest quarter
Maravai Lifesciences Holdings, Q3 2026: revenue $45.9M (+10% year over year), operating margin -45.0%, net loss $24.0M, operating cash flow $5.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Maravai Lifesciences Holdings raise or lower its guidance?
Maravai Lifesciences Holdings (MRVI) raised its guidance on Nov 4, 2026: Revenue $212M–$216M for FY2026; EBITDA $40.0M–$42.0M for FY2026.
What does Maravai Lifesciences Holdings expect?
We intend to continue investing in research and development to support our customers’ demand for innovation. In particular, we expect to incur meaningful share-based compensation expense in the future. We expect cost of revenue to remain below prior-year levels as a percentage of revenue as we continue to realize the benefits of our restructuring actions.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.